ANTICANCER RESEARCH 37: 5179-5185 (2017) doi:10.21873/anticanres.11940
Metallothionein Isoform Expression in Benign and Malignant Thyroid Lesions
BEATA WOJTCZAK1*, BARTOSZ PULA2*, AGNIESZKA GOMULKIEWICZ2, MATEUSZ OLBROMSKI2, MARZENA PODHORSKA-OKOLOW2, PAWEŁ DOMOSLAWSKI1, MAREK BOLANOWSKI3, JACEK DAROSZEWSKI3 and PIOTR DZIEGIEL2,4 1First
Department and Clinic of General, Gastroenterological and Endocrine Surgery, of Histology and Embryology, 3Department and Clinic of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland; 4Department of Physiotherapy, Wroclaw University School of Physical Education, Wroclaw, Poland 2Department
Abstract. Background: Metallothioneins (MTs) are involved
in numerous cell processes such as binding and transport of zinc and copper ions, differentiation, proliferation and apoptosis, therefore contributing to carcinogenesis. Scarce data exist on their expression in benign and malignant lesions of the thyroid. Materials and Methods: mRNA expression of functional isoforms of MT genes (MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1X, MT2A, MT4) was studied in 17 nodular goiters (NG), 12 follicular adenomas (FA) and 26 papillary thyroid carcinomas (PTC). Results: One-way ANOVA revealed significant differences in mRNA expression levels of MT1A (p